Last reviewed · How we verify
Aflibercept intravitreal injection
Aflibercept binds to vascular endothelial growth factors (VEGFs) and placental growth factor (PlGF), preventing their interaction with VEGF receptors and thus inhibiting angiogenesis and vascular permeability.
Aflibercept binds to vascular endothelial growth factors (VEGFs) and placental growth factor (PlGF), preventing their interaction with VEGF receptors and thus inhibiting angiogenesis and vascular permeability. Used for Neovascular (wet) age-related macular degeneration, Macular edema following retinal vein occlusion.
At a glance
| Generic name | Aflibercept intravitreal injection |
|---|---|
| Sponsor | Innostellar Biotherapeutics Co.,Ltd |
| Drug class | VEGF inhibitor |
| Target | VEGF-A, VEGF-B, PlGF |
| Modality | Biologic |
| Therapeutic area | Ophthalmology |
| Phase | Phase 2 |
Mechanism of action
By sequestering VEGF and PlGF, aflibercept reduces the formation of new blood vessels and leakage from existing ones, which is particularly useful in treating ocular diseases characterized by abnormal blood vessel growth and leakage.
Approved indications
- Neovascular (wet) age-related macular degeneration
- Macular edema following retinal vein occlusion
Common side effects
- Conjunctival hemorrhage
- Eye pain
Key clinical trials
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003) (PHASE2, PHASE3)
- 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration (PHASE3)
- High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes (PHASE4)
- Acute Intra Ocular Pressure Monitoring After Aflibercept 8mg/0.07mL (NA)
- Speculum-Free Intravitreal Injection Using Cotton-Tipped Applicator Retraction: A Randomized Trial of Pain, Procedure Time, Patient Satisfaction, and Safety (NA)
- COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME (PHASE3)
- Safety and Efficacy Evaluation of LX111 Gene Therapy in DME Patients (EARLY_PHASE1)
- A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: